ProMIS Neurosciences (NASDAQ:PMN) Stock Price Up 4% – Time to Buy?

ProMIS Neurosciences, Inc. (NASDAQ:PMN) shares traded up 4% on Tuesday . The stock traded as high as $1.06 and last traded at $1.04. 39,830 shares changed hands during trading, a decline of 44% from the average session volume of 70,514 shares. The stock had previously closed at $1.00.

ProMIS Neurosciences Price Performance

The stock’s 50-day moving average is $1.24 and its two-hundred day moving average is $1.64. The company has a market cap of $19.72 million, a P/E ratio of -1.41 and a beta of 0.61.

ProMIS Neurosciences (NASDAQ:PMN) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.01. On average, analysts predict that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current year.

Insiders Place Their Bets

In other ProMIS Neurosciences news, Director Madge K. Shafmaster purchased 60,000 shares of ProMIS Neurosciences stock in a transaction dated Friday, September 20th. The stock was purchased at an average price of $1.25 per share, with a total value of $75,000.00. Following the transaction, the director now directly owns 68,333 shares of the company’s stock, valued at $85,416.25. This trade represents a 700.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Madge K. Shafmaster acquired 70,000 shares of ProMIS Neurosciences stock in a transaction dated Monday, September 23rd. The stock was purchased at an average cost of $1.28 per share, for a total transaction of $89,600.00. Following the purchase, the director now directly owns 138,333 shares of the company’s stock, valued at approximately $177,066.24. This trade represents a 100.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Madge K. Shafmaster bought 60,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were bought at an average price of $1.25 per share, for a total transaction of $75,000.00. Following the completion of the transaction, the director now directly owns 68,333 shares of the company’s stock, valued at $85,416.25. This represents a 700.00 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 140,000 shares of company stock valued at $177,100. Insiders own 6.39% of the company’s stock.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.